H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35

Futu NewsJan 8 20:34 · Ratings

Stoke Therapeutics' Promising Potential: Buy Rating Backed by Strong Phase 3 Trial Design and Positive Early Results

TipRanksJan 8 20:16 · Ratings

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Stoke TherapeuticsJan 8 13:00

Chardan Capital Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $24

Futu NewsJan 8 07:31 · Ratings

Stoke Therapeutics Down Over 15%, on Pace for Largest Percent Decrease Since February 2024 -- Data Talk

Dow JonesJan 8 04:17

Stoke Therapeutics Reports Alignment With Regulators for Dravet Syndrome Trial

MT NewswiresJan 8 00:19